Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Active, not recruiting
National Cancer Institute (NCI)
N/A
2010-10-01
This clinical trial is studying induction therapy followed by meta-iodobenzylguanidine (MIBG)
labeled with iodine-131 and chemotherapy in treating patients with newly diagnosed high-risk
neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy
with isotretinoin. Radioisotope therapy, such as MIBG labeled with iodine-131, releases
radiation that kills tumor cells. Drugs used in chemotherapy, such as cisplatin, etoposide,
busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. A peripheral stem cell transplant can
replace blood-forming cells that are damaged by MIBG labeled with iodine-131 and
chemotherapy.
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Active, not recruiting
Children's Oncology Group
N/A
2010-10-01
This clinical trial is studying induction therapy followed by meta-iodobenzylguanidine (MIBG)
labeled with iodine-131 and chemotherapy in treating patients with newly diagnosed high-risk
neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy
with isotretinoin. Radioisotope therapy, such as MIBG labeled with iodine-131, releases
radiation that kills tumor cells. Drugs used in chemotherapy, such as cisplatin, etoposide,
busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. A peripheral stem cell transplant can
replace blood-forming cells that are damaged by MIBG labeled with iodine-131 and
chemotherapy.
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Active, not recruiting
New Approaches to Neuroblastoma Therapy Consortium
Phase 2
2014-07-01
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG)
and compare their effects on tumor response and associated side effects, to determine if one
therapy is better than the other for people diagnosed with relapsed or persistent
neuroblastoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
